Pancreatic Neoplasms

Inclusion Criteria

- Male or female patients ≥18 years of age
 - Histological or cytologically confirmed locally advanced, inoperable or metastatic pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery
 - Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to RECIST, Version 1.1
 - Resolution of all acute toxic effects of any prior local treatment to Common Terminology Criteria for Adverse Events (CTCAE) Grade </= 1
 - Eastern Cooperative Oncology Group performance status (ECOG PS) </= 2
 - Patient has cardiac function, within normal range, as measured by an echocardiogram

Exclusion Criteria

- Known history of, or symptomatic metastatic brain or meningeal tumors
 - History of cardiac disease
 - Active clinically serious infections 
 - Clinically significant (ie. symptomatic) peripheral vascular disease
 - Pregnant or lactating women; women of childbearing potential not employing adequate contraception
 - Use of strong inhibitors or inducers of CYP3A4
 - Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic cancer, or other malignancy
 - Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers to radiation therapy in adjuvant intention if given within 6 months from start of study treatment
 - Thrombotic or embolic events such within 6 months prior to start of study treatment